Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B
Authors:
- Satoshi ShakadoSSSatoshi Shakado
- Takashi TanakaTTTakashi Tanaka
- Daisuke MoriharaDMDaisuke Morihara
- Shinya NishizawaSNShinya Nishizawa
- Shinjiro InomataSIShinjiro Inomata
- Syuichi UedaSUSyuichi Ueda
- Teruo MatsumotoTMTeruo Matsumoto
- Akira AnanAAAkira Anan
- Yasuaki TakeyamaYTYasuaki Takeyama
- Makoto IrieMIMakoto Irie
- Kaoru IwataKIKaoru Iwata
Open Access
- 30 May 2008
- journal article
- research article
- Published by Springer Nature in Hepatology International
- Vol. 2 (3) , 361-369
Abstract
Purpose This study aimed to clarify the long-term efficacy of the lamivudine treatment in Japanese patients with chronic hepatitis B either with or without lamivudine resistance or with or without adefovir add-on treatment. Methods We followed 110 patients who received lamivudine for more than 12 months, including 67 hepatitis B e antigen (HBeAg)-positive and 43 HBeAg-negative patients. Results The median follow-up after the onset of lamivudine was 48 (range = 12–86) months. In all the patients with or without lamivudine resistance, the level of alanine aminotransferase (ALT) normalization decreased from 70.0% at 1 year to 36.4% at 5 years and the loss of serum HBV DNA level decreased from 72.7% at 1 year to 31.8% at 5 years. Sixty patients (54.6%) developed a lamivudine-resistant mutation, and this occurrence was more frequently observed in those who were HBeAg-positive (P < 0.01), those with a low level of ALT (P < 0.05), and those with a high level of serum HBV DNA (P < 0.01). Thirty-six of 60 patients received adefovir in addition to lamivudine to treat breakthrough hepatitis. A Cox proportional hazards model analysis revealed the level of baseline HBV DNA to be the best predictive factor for the virus recrudescence (risk ratio = 0.466, 95% confidence interval [CI]: 0.246–0.842, P = 0.011) and the breakthrough hepatitis (risk ratio = 0.444, 95% CI: 0.218–0.879, P = 0.019). We carefully monitored the efficacy of this treatment both in patients who received adefovir and in those who did not since the beginning of the lamivudine treatment. The normalization level of ALT was 61.4% at 5 years and the loss of serum HBV DNA was 61.4% at 5 years since lamivudine was started. A histologic improvement was observed in patients with ALT levels less than two times the upper limit of normal at the time of a second liver biopsy. Conclusions Although the efficacy of lamivudine is limited because of breakthrough hepatitis, adefovir was used as a salvage treatment of patients with lamivudine-resistant chronic hepatitis B. In addition, lamivudine was used for the treatment of Japanese patients with chronic hepatitis B with or without lamivudine resistance, and was found to be useful regarding the long-term virologic and biochemical responses.Keywords
This publication has 24 references indexed in Scilit:
- Long‐term therapy with adefovir dipivoxil in hepatitis B e antigen‐negative patients developing resistance to lamivudineAlimentary Pharmacology & Therapeutics, 2007
- Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis BHepatology, 2007
- Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral LoadGastroenterology, 2006
- Durability of Serologic Response After Lamivudine Treatment of Chronic Hepatitis BHepatology, 2003
- Effect of virological response on post‐treatment durability of lamivudine‐induced HBeAg seroconversionJournal of Viral Hepatitis, 2002
- Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis BHepatology, 2000
- Acute Exacerbation of Chronic Hepatitis B Virus Infection After Withdrawal of Lamivudine TherapyHepatology, 2000
- Two-year follow-up study after treatment with lamivudine for chronic hepatitis B: seven cases reportedHepatology Research, 2000
- Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trialGut, 2000
- Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapyHepatology, 1999